News

A rare gene mutation that delays Alzheimer’s disease does so by damping inflammatory signaling in brain-resident immune cells, according to a preclinical study led by investigators at Weill Cornell Medicine. The finding adds to growing evidence that brain inflammation is a major driver of neurodegenerative disorders such as Alzheimer’s—and that it may be a key therapeutic target for these disorders.

In the study, published June 23 in Immunity, the researchers examined the effects of...

Using an algorithm they call the Krakencoder, researchers at Weill Cornell Medicine are a step closer to unraveling how the brain’s wiring supports the way we think and act. The study, published June 5 in Nature Methods, used imaging data from the Human Connectome Project to align neural activity with its underlying circuitry.

Mapping how the brain’s anatomical connections and activity patterns relate to behavior is crucial not only for understanding how the brain works generally but...

At the 12th annual Helen and Robert Appel Alzheimer’s Disease Research Institute Symposium, scientists and clinicians shared their latest research which is advancing how Alzheimer’s disease is diagnosed and treated. Held at Weill Cornell Medicine’s Griffis Faculty Club, the symposium gave investigators and community members the opportunity to learn and ask questions about new directions in neurodegenerative research. Alzheimer’s disease affects more than 7 million Americans, a...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.

Now, a team of researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) is expanding the understanding of how the treatment works — an understanding that could help improve the effectiveness of immunotherapies more broadly.